Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.67 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.65 |
| ▸ | CNR1 | P21554 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.58 |
| ▸ | CASP2 | P42575 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12201237 | 0.96 | CNR1 (0.69) | CNR1KDM4E | |
| SCHEMBL8541977 | 0.91 | EPHX2 (0.72) | EPHX2SLC6A5CNR1KDM4ELPAR1 | |
| SCHEMBL8541979 | 0.91 | EPHX2 (0.72) | EPHX2SLC6A5CNR1KDM4ELPAR1 | |
| SCHEMBL889142 | 0.91 | CASP2 (0.69) | EPHX2CASP2 | |
| SCHEMBL889146 | 0.91 | CASP2 (0.69) | EPHX2CASP2 | |
| SCHEMBL889190 | 0.91 | CASP2 (0.69) | EPHX2CASP2 | |
| SCHEMBL889144 | 0.91 | CASP2 (0.69) | EPHX2CASP2 | |
| SCHEMBL889185 | 0.91 | CASP2 (0.69) | EPHX2CASP2 | |
| SCHEMBL889128 | 0.91 | CASP2 (0.69) | EPHX2CASP2 | |
| SCHEMBL889130 | 0.91 | CASP2 (0.69) | EPHX2CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034376-B2 | Lipid containing formulations | Alnylam Pharamaceticals, Inc. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20090023673-A1 | LIPID CONTAINING FORMULATIONS | BANK OF AMERICA, N.A. | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023673-A1 | LIPID CONTAINING FORMULATIONS | LIPA, POLRMT, PHOSPHO1 | EPHX2 2624/4885SLC6A5 3003/4885CNR1 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.